Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Dividend stocks have a well-earned reputation for outperformance. Modern portfolio theory (MPT), however, indicates that growth investors should strictly adhere to a couple of critical guidelines when picking dividend stocks for their portfolios. Among the most important guideposts recommended by the peer-reviewed MPT literature are selecting stocks with dividends lower than the average of the benchmark S&P 500 index; selecting stocks with premium valuations and a track record of positive annual returns; and selecting stocks in fast-growing sectors like healthcare or technology.